Filing Details
- Accession Number:
- 0001654954-17-011653
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2017-12-14 16:12:44
- Reporting Period:
- 2017-12-12
- Accepted Time:
- 2017-12-14 16:12:44
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1410098 | Cormedix Inc. | CRMD | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1488011 | A. Gary Gelbfish | C/O Cormedix Inc. 1430 U.s. Highway 206, Suite 200 Bedminster NJ 07921 | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock, $0.001 Par Value Per Share | Acquisiton | 2017-12-12 | 52,083 | $0.48 | 2,101,121 | No | 4 | P | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | P | Direct |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Stock, $0.001 Par Value Per Share | 14,000 | Indirect | Landmark Foundation |
Reported Derivative Holdings
| Sec. Name | Sec. Type | Price | Date | Expiration Date | Amount | Remaning Holdings | Nature of Ownership |
|---|---|---|---|---|---|---|---|
| Common Stock, $0.001 Par Value Per Share | Stock Option (Right to Buy Common Stock) | $0.37 | 2027-08-03 | 75,000 | 75,000 | Direct | |
| Common Stock, $0.001 Par Value Per Share | Series C-3 Non-Voting Convertible Preferred Stock | $0.00 | 2014-01-08 | 500,000 | 50,000 | Direct | |
| Common Stock, $0.001 Par Value Per Share | Warrant (Right to Purchase Common Stock) | $0.90 | 2015-01-08 | 2020-01-08 | 250,000 | 250,000 | Direct |
| Common Stock, $0.001 Par Value Per Share | Series A Common Stock Warrant | $0.75 | 1,000,000 | 1,000,000 | Direct | ||
| Common Stock, $0.001 Par Value Per Share | Series B Common Stock Warrant | $1.05 | 1,000,000 | 1,000,000 | Direct |
| Expiration Date | Amount | Remaning Holdings | Nature of Ownership |
|---|---|---|---|
| 2027-08-03 | 75,000 | 75,000 | Direct |
| 500,000 | 50,000 | Direct | |
| 2020-01-08 | 250,000 | 250,000 | Direct |
| 1,000,000 | 1,000,000 | Direct | |
| 1,000,000 | 1,000,000 | Direct |
Footnotes
- Purchase was contracted on November 17, 2017, but not closed until December 12, 2017.
- Held by Landmark Foundation, of which Dr. Gelbfish and his wife are trustees.
- These options vest as follows: 1/3 on August 3, 2017, an additional 1/3 on August 3, 2018, and the remaining 1/3 on August 3, 2019.
- The conversion ratio is equal to the stated value of $10.00 divided by the conversion price of $1.00. The Series C-3 Non-Voting Convertible Preferred Stock is perpetual.
- The Series A Common Stock warrant is exercisable any time after the Company publicly announces through the filing of a Current Report on Form 8-K that the Company has received Stockholder Approval and the amendment to the Company's Certificate of Incorporation has become effective (the "Initial Exercise Date"). The warrant shall be exercisable for a period of thirteen months from the Initial Exercise Date.
- The Series B Common Stock warrant is exercisable any time after the Company publicly announces through the filing of a Current Report on Form 8-K that the Company has received Stockholder Approval and the amendment to the Company's Certificate of Incorporation has become effective (the "Initial Exercise Date"). The warrant shall be exercisable for a period of five years from the Initial Exercise Date.
Billionaire Hedge Funds
